3-ethyl-5-(1,4,5,6-tetrahydropyrimidin-6-yl)-1,2,4-oxadiazole,hydrochloride structure
|
Common Name | 3-ethyl-5-(1,4,5,6-tetrahydropyrimidin-6-yl)-1,2,4-oxadiazole,hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 1196130-86-5 | Molecular Weight | 216.66800 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C8H13ClN4O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 3-ethyl-5-(1,4,5,6-tetrahydropyrimidin-6-yl)-1,2,4-oxadiazole,hydrochlorideCDD0102 HCl is a selective and potent M1 muscarinic receptor agonist for the treatment of Alzheimer's disease. |
| Name | 3-ethyl-5-(1,4,5,6-tetrahydropyrimidin-6-yl)-1,2,4-oxadiazole,hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | CDD0102 HCl is a selective and potent M1 muscarinic receptor agonist for the treatment of Alzheimer's disease. |
|---|---|
| In Vitro | In cell lines expressing M1 receptors, CDD0102 (CDD-0102) is an efficacious muscarinic agonist. CDD0102 exhibits much lower activity at M3 and M5 receptors[1]. |
| In Vivo | Following i.p. injections, CDD0102 (CDD-0102) crosses the blood-brain barrier (BBB) in a dose-dependent manner. The LD50 of CDD0102 is 190 mg/kg in toxicological studies after i.p. injections and greater than 1,000 mg/kg following oral administration. In follow-up studies, CDD0102 fully reverses memory deficits associated with IgG-192 saporin administration after oral administration at a dose of 10 mg/kg. No side effects are observed at this dose[1]. |
| References | 1. Messer WS Jr. The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):187-93. |
| Molecular Formula | C8H13ClN4O |
|---|---|
| Molecular Weight | 216.66800 |
| Exact Mass | 216.07800 |
| PSA | 63.31000 |
| LogP | 1.26110 |
| InChIKey | FVWAMONNJGNNHY-UHFFFAOYSA-N |
| SMILES | CCc1noc(C2CN=CNC2)n1.Cl |
| MCD-386CR |
| CDD-0102 hydrochloride |
| UNII-6P87MRR8OA |